# Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

> **NCT06821100** · PHASE1 · RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 75 (estimated)

## Conditions studied

- Vaccine Response
- COVID-19 Vaccine
- Immune Response to Covid 19 Vaccination

## Interventions

- **DRUG:** Thymalfasin (Thymosin alpha 1, Ta1)

## Key facts

- **NCT ID:** NCT06821100
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821100, "Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06821100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*